GM2 Gangliosidosis, often known as Tay-Sachs disease, is caused by a mutation in the HEXA genes, which results in muscular atrophy. Because this disease has no known cure, therapy is mainly symptom-based. Some of the signs and symptoms include exaggerated reactions to loud noises, seizures, loss of movement, vision, and hearing, mucus collection in the lungs, and other symptoms. Tay-Sachs disease is also known as hexosaminidase disease. A deficiency is a rare inherited neurological disease caused by a loss of the enzyme hexosaminidase A, which results in the accumulation of G2 gangliosides.
The report " Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
Key Highlights:
- Axovant Sciences, Inc. released clinical data for AXO-AAV-GM2, a gene therapy for Tay-Sachs disease, in March 2019. In a 30-month-old kid with advanced infantile Tay-Sachs disease, the trial showed that it was well tolerated with no significant adverse effects.
- IntraBio Inc. submitted an Investigational New Drug (IND) application to the FDA in February 2019 for IB1001-202 to treat Tay-Sachs and Sandhoff Disease. The IND approval is a huge step forward for both the patients and the researchers.
Analyst View:
The market's expansion is due to the rising occurrence of genetic disease, particularly among newborns. Additionally, increased investment in R&D activities to develop new treatment options to cure the genetic disorder, as well as the release of new and improved medications to treat the disease's symptoms and consequences, are likely to propel market growth. The industry could be boosted by high demand for disease-specific novel treatments. Market growth is being boosted by the release of drugs to treat GM2 Gangliosidosis-related problems.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-GM2-Gangliosidosis-Market-4727
Key Market Insights from the report:
The Global GM2 Gangliosidosis Market is segmented based on the type, therapeutic, drugs, and region.
- By Type, the Global GM2 Gangliosidosis Market is segmented into Infantile, Juvenile and Adults.
- By Therapeutic, the market is segmented in Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy.
- By Drugs, the Global GM2 Gangliosidosis Market is segmented into Anticonvulsant, Antipsychotic medication and Others.
- By Region, the Global GM2 Gangliosidosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. the market in North America is expected to increase significantly.
Competitive Landscape:
The key players operating in the global GM2 Gangliosidosis market includes Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Novartis AG, and others. Recursion Pharmaceuticals, Inc., IntraBio Inc., Johnson & Johnson Services, Inc., and Axovant Sciences, Inc.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
About Prophecy Market Insights
Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.
Some Important Points Answered in this Market Report Are Given Below:
- Explains an overview of the product portfolio, including product development, planning, and positioning.
- Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
- Detailed analysis of the market revenue over the forecasted period.
- Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
- Study on the segments that are anticipated to dominate the market.
- Study on the regional analysis that is expected to register the highest growth over the forecast period.
Key Topics Covered
- Introduction
- Study Deliverables
- Study Assumptions
- Scope of the Study
- Research Methodology
- Executive Summary
- Opportunity Map Analysis
- Market at Glance
- Market Share (%) and BPS Analysis, by Region
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Investment Analysis
- Competitive Analysis
To know more
Contact Us:
Sales
Prophecy Market Insights
1 860 531 2701
Email- This email address is being protected from spambots. You need JavaScript enabled to view it.
